Yu Jing

Yujing Biotechnology is a Beijing-based biotechnology company focused on drug discovery for "undruggable" targets using a combination of cryo-electron microscopy (cryo-EM) and artificial intelligence. Founded in 2021 by structural biologist Professor Hongwei Wang, the company specializes in resolving the high-resolution structures of complex membrane proteins, including GPCRs and ion channels. Their platform utilizes these structural insights to drive the rational design of novel small molecule therapeutics through AI-enhanced screening and optimization. Yujing's primary therapeutic focus includes oncology, immunology, and metabolic diseases, where they aim to develop first-in-class or best-in-class treatments. The company has attracted significant investment from prominent venture capital firms to expand its structural biology infrastructure and pipeline.